天賜材料(002709.SZ):子公司擬3.76億元投建年產8萬噸鋰電添加劑材料項目
格隆匯1月13日丨天賜材料(002709.SZ)公佈,公司於2023年1月12日召開了第五屆董事會第四十五次會議、第五屆監事會第三十七次會議,審議通過了《關於投資建設年產8萬噸鋰電添加劑材料項目的議案》,子公司九江天賜使用自籌資金投資建設“年產8萬噸鋰電添加劑材料項目”,項目建設週期為18個月,項目總投資約3.76億元,其中建設投資為2.68億元,鋪底流動資金為1.08億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.